NCT05786924: Phase 1/2 Trial of S241656 in Selected RAS/MAPK Mutation- Positive Malignancies
- State
- Under way
- Phase
- Phase 1 and Phase 2
- People
- 623 planned
- Started
- 18 Apr 2023
- Primary completion
- Jun 2028
- Arms
- Part 1F: Dose Escalation with Trametinib in Solid Tumors
- Results
- None posted
- 28 Mar 2023: Trial registered
- 18 Apr 2023: Trial started